---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-000864"
form_type: "8-K"
ticker: "PAHC"
cik: "0001069899"
company_name: "PHIBRO ANIMAL HEALTH CORP"
filed_at: "2024-02-07T23:59:59+00:00"
generated_at: "2026-06-06T06:24:01.838911+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Phibro reports Q2 diluted EPS of $0.03 on net income of $1.3M; reaffirms adjusted EBITDA guidance

## Summary
- Net sales $249.9M (+2% YoY); Animal Health segment up 6% led by 31% vaccine growth.
- GAAP net income $1.3M, diluted EPS $0.03, down from $7.2M and $0.18 a year ago.
- Adjusted EBITDA $29.5M (-5% YoY); adjusted diluted EPS $0.33 (-2%).
- FY2024 guidance: reaffirmed adjusted EBITDA $106-$112M; GAAP net income lowered to $12-$17M (down 55%).
- Includes $4.2M Brazil employment tax litigation charge and $7.5M foreign currency losses from Argentina devaluation.

## SEC filing metadata
- accession: 0001558370-24-000864
- form_type: 8-K
- ticker: PAHC
- cik: 0001069899
- company_name: PHIBRO ANIMAL HEALTH CORP
- filed_at: 2024-02-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069899/000155837024000864/0001558370-24-000864-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069899/000155837024000864/pahc-20240207x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-000864
- JSON: https://secwatch.observer/filing/0001558370-24-000864.json
- Plain text: https://secwatch.observer/filing/0001558370-24-000864.txt

## Key facts
- Earnings Releases
  PHIBRO ANIMAL HEALTH CORP reported the fiscal quarter ended December 31, 2023 results: revenue $249.9 million, net income $1.3 million, EPS $0.03. Guidance reaffirmed.
  - Period: the fiscal quarter ended December 31, 2023
  - Revenue: $249.9 million
  - Net income: $1.3 million
  - EPS: $0.03
  - Guidance: reaffirmed
  - Result: reported results
  source text: guidance for the year ending June 30, 2024. ​ Highlights for the three months ended December 31, 2023 (compared to the three months ended December 31, 2022) ​ - Net sales of $249.9 million, an increase of $5.3 million, or 2% - Net income of $1.3 million, a decrease of $5.9 million - Diluted earnings per share of $0.03, a decrease of $0.15 - Adjusted EBITDA of $29.5
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069899/000155837024000864/0001558370-24-000864-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.